diabetestalk.net

Mental Health Care In Pediatric Diabetes: Overcoming Challenges And Barriers

Mental Health Care in Pediatric Diabetes: Overcoming Challenges and Barriers

Mental Health Care in Pediatric Diabetes: Overcoming Challenges and Barriers


Mental Health Care in Pediatric Diabetes: Overcoming Challenges and Barriers
Evidence-Based Diabetes Management > June 2017 Published on: June 21, 2017
Mental Health Care in Pediatric Diabetes: Overcoming Challenges and Barriers
The American Diabetes Association recently recognized the important role that psychosocial care plays in diabetes management. Addressing behavioral health needs at all stages of development in youth with diabetes is critical.
The financial burden of poorly controlled diabetes in childhood and adolescence is not fully evident until complications occur during adulthood. In 2010, researchers estimated that the annual cost of type 1 diabetes (T1D) in the United States was $14.4 billion, including medical costs and lost income.1Prevention of diabetes-related complications requires that providers who care for children and adolescents with diabetes address barriers to good control soon after diagnosis and at frequent intervals as patients progress developmentally.
As a self-management disease, diabetes requires patients to adjust their insulin regimens based on blood glucose patterns they have recognized (in relation to exercise, illness, type of foods eaten, etc). This requires the synthesis of information from different sources and depends upon cognitive function and attention to detail. Even with the most advanced technology (insulin pumps, continuous glucose monitors, and hybrid closed loop systems), neurodevelopmental and behavioral issues can interfere with a childs ability to master diabetes self-management skills.2
Prevalence of Mental Hea Continue reading

Rate this article
Total 1 ratings
Diagnostic accuracy of resting systolic toe pressure for diagnosis of peripheral arterial disease in people with and without diabetes: a cross-sectional retrospective case-control study

Diagnostic accuracy of resting systolic toe pressure for diagnosis of peripheral arterial disease in people with and without diabetes: a cross-sectional retrospective case-control study

Abstract
The resting systolic toe pressure (TP) is a measure of small arterial function in the periphery. TP is used in addition to the ankle-brachial index when screening for peripheral arterial disease (PAD) of the lower limb in those with diabetes, particularly in the presence of lower limb medial arterial calcification. It may be used as an adjunct assessment of lower limb vascular function and as a predictor of wound healing. The aim of this study was to determine the diagnostic accuracy of TP for detecting PAD in people with and without diabetes.
This was a retrospective case-control study. Two researchers extracted information from consecutive patient records, including TP measurements, colour Duplex ultrasound results, demographic information, and medical history. Measures of diagnostic accuracy were determined by receiver operating curve (ROC) analysis, and calculation of sensitivity, specificity, and positive and negative likelihood ratios.
Three hundred and nintey-four participants with suspected PAD were included. In the diabetes group (n = 176), ROC analysis of TP for detecting PAD was 0.78 (95%CI: 0.69 to 0.84). In the control group (n = 218), the ROC of TP was 0.73 (95%CI: 0.70 to 0.80). TP had highest sensitivity when anatomical distribution of disease was both proximal and distal (diabetes group: 79.49%, the control group: 82.61%). TP yielded highest sensitivity in mild disease (50–75% stenosis) in diabetes group, (81.82%) and moderate disease (>75% stenosis) in control group (80.77%).
Our findings indicate that TPs are useful to assist in diagnosing PAD Continue reading

Best Breakfast Tips For Gestational Diabetics

Best Breakfast Tips For Gestational Diabetics

If you are detected with diabetes while being pregnant, this is known as gestational diabetics. It occurs in 7% of women. Gestational diabetes, if not treated in the early stage can lead to complications in the later date. Women with the controlled limit in blood sugar deliver healthy babies. When the carbohydrate restriction in blood does not burn calories, then it leads to diabetes. Glucose is considered as the primary source of energy for the body. Still, it is considered as the enemy of diabetes.
What are the foods that should be avoided during the gestational period?
If you have gestational diabetes, then you should avoid some foods like- milk, yogurt, fruits, juices, rice, grains, cereals, pasta, bread, tortillas, bagels, rolls, split beans, dried beans, lentils, corn, yams, potatoes, winter squash, and peas.
What are the primary dietary considerations while opting for a diet in gestational period?
Your physician will prescribe you certain food and calculate some carbohydrates you need at meals. There are some facts which you need to keep in mind while opting for a healthy diet.
Divide your day and your meals accordingly into three main and two snacks.
The carbohydrate intake of your lunch should be reasonably small.
Drink one cup of milk a day and restrict the amount.
Limit the portion of fruit you eat.
Mind your breakfast menu and eat accordingly.
Limit the intake of sweets and desert.
Use artificial sweetener instead of natural sugar.
Some useful breakfast ideas for gestational diabetics
In case you have gestational diabetes, then you have to stress a lot of the in Continue reading

New alginate skin patch for type 2 diabetes

New alginate skin patch for type 2 diabetes


Home / Innovations / New alginate skin patch for type 2 diabetes
New alginate skin patch for type 2 diabetes
Concept illustration of microneedle device for type 2 diabetes treatment. Chen lab, NIBIB.
or millions of people with type 2 diabetes, ongoing vigilance over the amount of sugar, or glucose, in their blood is the key to health. A finger prick before mealtimes and maybe an insulin injection is an uncomfortable but necessary routine.
Researchers with NIHs National Institute of Biomedical Imaging and Bioengineering (NIBIB) have devised an innovative biochemical formula of mineralized compounds that interacts in the bloodstream to regulate blood sugar for days at a time. In a proof-of-concept study performed with mice, the researchers showed that the biochemically formulated patch of dissolvable microneedles can respond to blood chemistry to manage glucose automatically.
This experimental approach could be a way to take advantage of the fact that persons with type 2 diabetes can still produce some insulin, said Richard Leapman, Ph.D., NIBIB scientific director. A weekly microneedle patch application would also be less complicated and painful than routines that require frequent blood testing.
Global incidence of all types of diabetes is about 285 million people, of which 90 percent have type 2 diabetes. Many require insulin therapy thatis usually given by injection just under the skin in amounts that are calculated according to the deficit in naturally generated insulin in the blood. Insulin therapy is not managed well in half of all cases.
NIBIB researchers led Continue reading

Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes

Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes


Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
: LLY) once-weekly Trulicity (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. The
(FDA) included the changes to the approved product labeling to reflect this important information for prescribers. Trulicity is available in a prefilled pen in 0.75 and 1.5 mg doses.
"Despite best efforts to manage their A1C, many adults with type 2 diabetes may need to add to or change their treatment plan to help them reach their blood sugar goals," said
, M.D., vice president, Global Medical Affairs, Lilly Diabetes. "They now have the option to use Trulicity, with its powerful efficacy in a once-weekly, easy-to-use pen,* along with basal insulin for even greater control."
Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes. It should be used along with diet and exercise.
Trulicity is not recommended as the first medication to treat diabetes. It has not been studied in people who have had inflammation of the pancreas (pancreatitis). It is not a substitute for insulin. Trulicity should not be used by people with type 1 diabetes, people with diabetic ketoacidosis, or people with a history of severe stomach or intestinal problems. It has not been studied in Continue reading

No more pages to load

Popular Articles

Related Articles